Dopaminergic denervation in de-novo Parkinson’s disease. Does functional somatotopy plays a role?
Objective: To clarify how dopaminergic denervation occurs along the dorsoventral axis of the posterior putamen in the earliest stages of PD. Background: Dopamine loss in…Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients with Parkinson’s Disease
Objective: To investigated functional connectivity pattern changes in M1 subregions and relationships to improved clinical symptoms following levodopa administration. Background: The primary motor cortex (M1)…The role of dopamine mis-metabolism in preclinical Parkinson’s disease olfactory deficits
Objective: To gain an understanding of the underlying pathological mechanisms of Parkinson’s disease (PD)-related hyposmia using post-mortem human olfactory bulbs and an in vivo model…Characterization of striatal dopaminergic neurotransmission in the rat pre-formed fibril models of Parkinson’s disease
Objective: To determine the longitudinal effects of synucleinopathy and synucleinopathy-triggered nigrostriatal degeneration on basal and evoked striatal dopamine (DA) release in the striatum at 4…Increased risk of Parkinson’s disease in patients with schizophrenia spectrum disorders
Objective: To investigate the coincidence of Parkinson’s disease (PD) and schizophrenia spectrum disorders (SCD). Background: PD is characterized by a progressive loss of mesostriatal dopamine…Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease
Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson’s disease
Objective: To report 18-month safety and clinical outcomes from a phase 1, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor fluctuations.…A Case of Improved Psychotic Depression and Motor Symptoms in Parkinson’s Disease following Electroconvulsive Therapy (ECT)
Objective: To describe a case of motoric, affective, and psychotic symptoms improving in PD following ECT. Background: Parkinson’s disease (PD) is a neurodegenerative disease caused…Impedance Doesn’t Change with Levodopa Treatment
Objective: We aimed to evaluate the impedance of patients on their best ON/worst OFFs with levodopa, assuming that the level of dopamine at electrode’s vicinity…Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: We aim to overcome these challenges by demonstrating that continuous i.c.v. of Anaerobic-dopamine (A-dopamine,Patent #WO2015173258 A1) close to the striatum is a feasible and…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 26
- Next Page »